ArticlePharmacology2025
Amphotericin-A21 Induces Antineoplastic Effects through the Modulation of Apoptosis in Human Tumoral Cells.
Article in Pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: While the high morbidity of cancer continues to affect the global population, there are currently no effective and safe therapeutic options. Amphotericin-A21 (AmB-A21) is a derivative of amphotericin B (AmB). Its efficacy is similar to that of its precursor, but it has greater safety. AmB-A21 can induce apoptosis in neoplastic cells, meaning it could potentially be employed as a safe chemotherapeutic agent.
methodsThis study examined the antineoplastic effect of AmB-A21 on MCF-7, U-87MG, and A-549 cells by evaluating cytotoxicity, apoptosis, and protein expressions associated with cell death. MCF-7 cells were treated with AmB-A21 at 40 µ<sc>m</sc>, U-87MG cells with AmB-A21 at 423 µ<sc>m</sc>, and A-549 cells with AmB-A21 at 192 µ<sc>m</sc> for all experiments. Non-treated cells were used as negative control. Comparative studies using AmB and cisplatin were also carried out.
resultsAmB-A21 reduced cell viability in a time-dependent manner. At 72 h, cell viability was reduced by 67% in MCF-7, 48% in U-87MG, and 47% in A-549 cells. AmB-A21 induced apoptosis by 50%, 58%, and 80% in MCF-7, U-87MG, and A-549 cells, respectively. A significant reduction in Bcl-2 expression and an important increase in Bax expression (55%/2.8-fold in MCF-7 cells, 40%/3.5 fold in U-87MG cells, and 45%/4.5-fold in A-549 cells) were also observed. AmB-A21 likewise increased caspase 9 activity 8.5-fold in MCF-7 cells, 4.1-fold in U-87MG cells, and 8-fold in A-549 cells.
conclusionAlthough comparatively AmB-A21 concentration for U-87MG cells was higher, it has potential for cancer therapy due to its safer profile. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.